## MAASAI MARA UNIVERSITY

# UNIVERSITY EXAMINATIONS 2022/2023 FOURTH YEAR SECOND SEMESTER EXAMINATION FOR THE DEGREE OF

## **BACHELOR OF SCIENCE IN APPLIED STATISTICS**

## **STA 4245: SURVIVAL ANALYSIS**

TIME: 2 HOURS

# INSTRUCTIONS: Answer question ONE and any other TWO questions. Question One (30 Marks)

- a) The discrete random variable T has times T=0, 1, 2, 3 ... with corresponding survival functions  $S_i$  and probability mass function  $f_i$ .
  - i. Show that the expected time of failure E(T) can be given by  $\sum_{i>0} S_i$ . (3 marks)
  - ii. During one July it was very cold, and one day 25 students reported to JKUAT hospital with flu virus. Two students had only a mild dose, and were discharged immediately with medicine, but the other had to be admitted. The record number of days each student stayed in the hospital is given by the random variable T, as shown below

| No. of days in hospital t                             | 0 | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| No. of students who<br>were in hospital for t<br>days | 2 | 1 | 3 | 5 | 6 | 8 |

Determine the PMF f(t), the survival function S(t), the hazard function h(t) and the expectation E(T). (3 marks)

b) For a continuous random variable T the hazard function h(t) is given by:

$$h(t) = \frac{\alpha\beta(\alpha t)^{\beta-1} \text{ for } t > 0}{0 \text{ elsewhere}}$$

Determine an expression for the integrated hazard function H(t), the survival function S(t) and the PDF f(t) (4 marks)

c) Suppose that in a study of the efficacy of a new drug, 20 mice with tumours are given the drug. The experimenter decides to terminate the study after 15 mice have died. The survival times are, in weeks;

5 6 6 7 10 15 18 18 18 21

23 27 31 34 55 55+ 55+ 55+ 55+ 55+

Assume that the times to death of these mice follow the lognormal distribution, estimate the mean and standard deviation of the survival time. (6 marks)

d) The time taken by patients to wake up after being anaesthetised during minor surgeries can be modelled by random variable X (hours) with the probability density function f(x) being given by:

$$f(x) = \frac{\sec^2(x) \text{ for } 0 \le x \le \pi/4}{0 \text{ elsewhere}}$$

- i. Determine an expression from survival function S(x) (1 mark)
- ii. Hence use your result to show that a patient with take  $\pi/6$  hours to wake up will be given by  $\frac{3-\sqrt{3}}{3}$  (2 marks)
- iii. Also determine correct to two decimal places the probability that the wake up time will be between 12 and 24 minutes. (3 marks)
- e) Given the following proportional hazards regression model for mortality of a sample of life assurance policy holders.

 $h_i(t) = h_0(t)exp\{0.01(x_i - 25) + y_i - 0.06z_i\}$ where

 $h_i(t)$  denotes the hazard function for life i at duration t,

- $h_0(t)$  denotes the baseline hazard function at duration t,
- $x_i$  denotes the age of entry of life i

 $y_i = 1$  if life i is a smoker, otherwise zero

 $z_i$  = 1 if life i is female, zero if male

i. Determine the class of the lives to which the baseline hazard function applies

(2 marks)

- What does the model tell you about the relative risk of a male smoker aged 25 at entry compared to a male non-smoker aged 40 at entry? (Answer to 2 d.p.)
  (3 marks)
- iii. What does the model tell you about the relative risk of a female non-smoker aged 30 at entry compared to a male smoker aged 35 at entry? (Answer to 2 d.p.)
   (2 marks)

### Question Two (20 Marks)

a) For a continuous variable X with parameter vector  $\Phi$ , probability density function  $f(x, \Phi)$ , survival function  $S(x, \Phi)$ , and hazard function $(x, \Phi)$ . Show that

the logl-likelihood function l, based on a sample  $(x_1, x_2, ..., x_n)$  of which  $(x_1, x_2, ..., x_n)$  $\dots$ ,  $x_d$ ) is uncensored and  $(x_{d+1}, x_{d+2}, \dots, x_n)$  is censored, is given by (6marks)

$$l = \sum_{i=1}^{d} \ln[h(x_i, \Phi]] + \sum_{i=1}^{n} \ln[S(x_i, \Phi]]$$

b) A doctor treating patients with bone cancer desires to find out whether a new drug, drug B, is more effective in increasing the time to remission of patients, than drug A, which he has been using. He took two random samples of patients of group 1 was treated with drug A, and group 2 with drug B. We know that the time to remission X days can be modelled by the PDF

$$f(x) = \frac{\beta e^{-\beta x}}{0} \qquad \text{for } x > 0$$
elsewhere.

- i. Determine the CDF, the survival function and hazard function for the random variable X. (5 marks)
- ii. Show that if d of the times in the sample of 10 are uncensored, and the rest are censored, then the log likelihood function l can be expressed in the form

$$l = d \ln \beta - \beta \sum_{i=1}^{10} \mathbf{x}_i$$

and hence determine an expression for the maximum likelihood estimate  $\hat{\beta}$  of  $\beta$ . (4 marks)

iii. The times to remission of two groups are recorded by doctor as follows Group 1 (time in days) 19, 40, 11, 30\*, 6, 14, 6, 15, 25, 6\* Group 2 (time in days) 10, 179, 53, 9, 141, 37, 2, 384\*, 70, 44 \*indicates a censored time. Determine the maximum likelihood estimate of  $\beta$  for each sample of ten patients. Give each estimate correct to three decimal places. (5 marks)

### **Question Three (20 Marks)**

A clinical trial to evaluate the efficacy of maintenance chemotherapy for acute myelogenous leukemia (AML) was conducted. The following table shows times of remission (i.e. freedom from symptoms in a precisely defined sense) of AML patients received chemotherapy

9, 13, 13\*, 18, 23, 28\*, 31, 34, 45\*, 48, 161\*.

Observations with star (\*) are right censored.

- a) Calculate the Kaplan-Meier estimate for the survival probability S(48).
- b) Find a 95% log-transformed confidence interval for *S*(48). (8 marks)

(6 marks)

c) Calculate the 95% CI for S(48) using the formula

$$Var[S(t)] = \left\{ \left[ \hat{S}(t) \right]^2 \left[ 1 - \hat{S}(t) \right] \right\} / r(t)$$
 (6 marks)

# **Question Four (30 Marks)**

a) Thirty melanoma patients (stages 2 to 4) were studied to compare the immunotherapies BCG (Bacillus Calmette-Guerin) - Treatment 1 and Corynebacterium parvum - Treatment 2 for their abilities to prolong remission duration. The data is shown below:

| Patient | Treatment received | Remission<br>duration | Patient | Treatment received | Remission<br>duration |
|---------|--------------------|-----------------------|---------|--------------------|-----------------------|
| 1       | 1                  | 33.7+                 | 16      | 2                  | 16.0+                 |
| 2       | 1                  | 3.9                   | 17      | 2                  | 6.9                   |
| 3       | 1                  | 10.5                  | 18      | 2                  | 11.0+                 |
| 4       | 1                  | 5.4                   | 19      | 2                  | 24.8+                 |
| 5       | 1                  | 19.5                  | 20      | 2                  | 23.0+                 |
| 6       | 1                  | 23.8+                 | 21      | 2                  | 8.3                   |
| 7       | 1                  | 7.9                   | 22      | 2                  | 10.8+                 |
| 8       | 1                  | 16.9+                 | 23      | 2                  | 12.2+                 |
| 9       | 1                  | 16.6+                 | 24      | 2                  | 12.5+                 |
| 10      | 1                  | 33.7+                 | 25      | 2                  | 24.4                  |
| 11      | 1                  | 17.1+                 | 26      | 2                  | 7.7                   |
| 12      | 2                  | 8.0                   | 27      | 2                  | 14.8+                 |
| 13      | 2                  | 26.9+                 | 28      | 2                  | 8.2+                  |
| 14      | 2                  | 21.4+                 | 29      | 2                  | 8.2+                  |
| 15      | 2                  | 18.1+                 | 30      | 2                  | 7.8+                  |

Compare the survival distributions of the two treatments using both the Log rank and generalized Wilcoxon tests (10 marks)

| b) | Consider the | following | data of | patients | with | cancer   | of the  | ovary |
|----|--------------|-----------|---------|----------|------|----------|---------|-------|
| ~, | •••••••      |           |         | Particip |      | 00011001 | 01 0110 | 0.01  |

| i. |             | -       |                 | analysis of the | data |    | · ·          | iarks) |
|----|-------------|---------|-----------------|-----------------|------|----|--------------|--------|
| ii | Plot the th | hree su | irvival functio | ns              |      |    | (4 m         | iarks) |
| Y  | ear         | after   | Number          | Number          | lost | to | Number dying |        |
| d  | iagnosis    |         | entering        | follow-up       |      |    |              |        |
|    |             |         | interval        |                 |      |    |              |        |
| 0  | -1          |         | 718             | 0               |      |    | 132          | _      |
| 1  | -2          |         | 568             | 8               |      |    | 80           |        |
| 2  | -3          |         | 468             | 8               |      |    | 57           |        |
| 3  | -4          |         | 398             | 7               |      |    | 52           |        |
| 4  | -5          |         | 331             | 7               |      |    | 58           |        |
| 5  | -6          |         | 264             | 12              |      |    | 45           |        |
| 6  | -7          |         | 198             | 11              |      |    | 32           |        |
| 7  | -8          |         | 151             | 12              |      |    | 20           |        |
| 8  | -9          |         | 116             | 14              |      |    | 11           |        |
| 9  | -10         |         | 89              | 7               |      |    | 14           |        |
| 1  | 0-11        |         | 67              | 2               |      |    | 13           |        |
| 1  | 1-12        |         | 52              | 3               |      |    | 11           |        |
| 1  | 2-13        |         | 36              | 2               |      |    | 8            |        |
| 1  | 3-14        |         | 23              | 3               |      |    | 6            |        |
| 1  | 4-15        |         | 13              | 4               |      |    | 5            |        |
| 1  | 5+          |         | 2               | 1               |      |    | 1            |        |